BRIDGEWATER, N.J., July 25, 2019 /PRNewswire/ -- Insmed
Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases, today announced that it will release its second quarter
2019 financial results on Thursday, August
1, 2019.
Insmed management will host a conference call for investors
beginning at 8:30 a.m. ET on Thursday,
August 1, 2019 to discuss the financial results and provide
a business update.
Shareholders and other interested parties may participate in the
conference call by dialing (888) 317-6003 (domestic) or (412)
317-6061 (international) and referencing conference ID number
5579948. The call will also be webcast live on the company's
website at www.insmed.com.
A replay of the conference call will be accessible approximately
one hour after its completion through August
8, 2019 by dialing (877) 344-7529 (domestic) or (412)
317-0088 (international) and referencing replay access code
10133256. A webcast of the call will also be archived for 90 days
under the Investor Relations section of the company's website at
www.insmed.com.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product is ARIKAYCE®
(amikacin liposome inhalation suspension), which is approved in
the United States for the
treatment of Mycobacterium avium complex (MAC) lung disease
as part of a combination antibacterial drug regimen for adult
patients with limited or no alternative treatment options. MAC lung
disease is a rare and often chronic infection that can cause
irreversible lung damage and can be fatal. Insmed's earlier-stage
clinical pipeline includes INS1007, a novel oral reversible
inhibitor of dipeptidyl peptidase 1 with therapeutic potential in
non-cystic fibrosis bronchiectasis and other inflammatory diseases,
and INS1009, an inhaled formulation of a treprostinil prodrug that
may offer a differentiated product profile for rare pulmonary
disorders, including pulmonary arterial hypertension. For more
information, visit www.insmed.com.
Contact:
Blaine
Davis
Head of Investor Relations and Corporate Communications
Insmed Incorporated
(908) 947-2841
blaine.davis@insmed.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/insmed-to-host-second-quarter-2019-financial-results-conference-call-on-thursday-august-1-2019-300890416.html
SOURCE Insmed Incorporated